**FDA Potentially Hazardous Medications (non-USP 800 Drugs)**

***This is an SOP template specifically for animal-related hazardous drug use. This excludes use of all USP-800 drugs.***

|  |  |
| --- | --- |
| **Protocol Name/#:** | Click here to enter text. |
| **Date SOP was approved by PI/lab supervisor:** | Click here to enter a date. |
| **Principal Investigator:** | Click here to enter text. |
| **Location(s) covered by this SOP:** | Click here to enter text. |
| *(Building/Room Number)* |

1. **Name of Drug, Hazard(s) associated and Potential Route of Exposure**

[Example: Butorphanol Tartrate Injection – Acutely toxic (dermal), Reproductive Toxin]

1. **Exposure Prevention:**

PPE: [Enter PPE required. This can be copied and pasted if all PPE is the same for each protocol/process]

Special Handling Procedures: [Enter any special handling procedures (if any) here. If not, you can remove this section.

1. **What to do if Exposed:** alter this section as needed

For employee: Report to your supervisor how you were exposed and what you were exposed to. Seek medical attention, as needed. Bring SDS with you to medical care, if able. Employees cannot be seen for occupational injuries at Student Health Services. You must go to urgent care, emergency room, or see an approved physician. Your supervisor will need to fill out an [incident report](https://risk.oregonstate.edu/) with Insurance and Risk Management Services.

**Principal Investigator SOP Approval**

By signing and dating here the designee certifies that the Standard Operating Procedure (SOP) for Acutely Toxic Chemicals is accurate and effectively provides standard operating procedures for laboratory personnel.

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Signature Printed Name/Title Date

I have read and understand the content of this SOP:

|  |  |  |
| --- | --- | --- |
| **Name** | **Signature** | **Date** |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |